pharmaphorum

UCB bags FDA okay for first drug to treat rare disease TK2d

That research led to the FDA granting compassionate use of the doxecitine and doxribtimine treatment in Arturito Estopinan, ...
Fierce Pharma

On a roll, UCB picks up another rare disease FDA approval

UCB has scored an FDA approval for ultra-rare disease treatment Kygevvi, continuing the positive momentum for the Belgian ...
Pulmonology Advisor

FDA Approves Kygevvi for Thymidine Kinase 2 Deficiency

The FDA has approved Kygevvi (doxecitine and doxribtimine) for the treatment of TK2d in adults and pediatric patients with an age of symptom onset on or before 12 years.
GEN - Genetic Engineering and Biotechnology News

FDA Approves First Treatment for Rare Thymidine Kinase 2 Deficiency

FDA approved KYGEVVI, the first and only treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients.
Applied Clinical Trials Online

FDA Approves UCB’s Kygevi for TK2 Deficiency Based on Multi-Study Clinical Program Demonstrating Significant Survival and Motor Gains

Kygevi (doxecitine and doxribtimine) earned FDA approval as the first treatment for thymidine kinase 2 deficiency, supported by data from a Phase II trial and multiple retrospective studies showing ...
BioWorld

Metsera in the middle of Novo, Pfizer bidding war

Pfizer Inc. upped its original $7.3 billion September offer to buy Metsera Inc., but the obesity specialist maintained that a now-improved unsolicited bid by semaglutide developer Novo Nordisk A/S is ...
PharmExec

FDA Approves Kygevvi Becoming the First Treatment for Thymidine Kinase 2 Deficiency

UCB has announced FDA’s approval of Kygevvi (doxecitine and doxribtimine) for the treatment of adults and pediatric patients ...

U.S. FDA Approves KYGEVVITM (Doxecitine And Doxribtimine), The First And Only Treatment For Adults And Children Living With Thymidine Kinase 2 Deficiency (Tk2d)

The First And Only Treatment For Adults And Children Living With Thymidine Kinase 2 Deficiency (Tk2d). <li /> Approved indication: KYGEVVITM (doxecitine and doxribtimine) powder for oral solution (2 ...
MyHorryNews

U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

KYGEVVI™ (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 ...